Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego BERKELEY, US – MAINZ, Germany – January 14, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to […]
Mainz Biomed Provides Review of 2025 Highlights
Initiation of eAArly DETECT 2 – U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project Study Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, US – […]
DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s […]
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador BERKELEY, US and MAINZ, Germany – November 18, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of […]
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
BERKELEY, US and MAINZ, Germany – November 12, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world’s leading healthcare trade shows, taking place from 17–20 November, 2025, in […]
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
BERKELEY, US and MAINZ, Germany – November 10, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) taking place from 14–15 November, […]
Mainz Biomed to Attend 2025 Maxim Growth Summit
BERKELEY, US and MAINZ, Germany – October 15, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC. The prestigious […]
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, US and MAINZ, Germany – October 8, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces positive topline results from its feasibility study, examining a non-invasive blood-based screening […]
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
BERKELEY, US and MAINZ, Germany – September 30, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by […]
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study BERKELEY, US and MAINZ, Germany – September 23, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce the commercial launch of its flagship product, ColoAlert®, in Switzerland. This milestone […]
